The overall safety profile of Palbociclib is based on pooled data from 872 patients who received the drug in combination with endocrine therapy (N = 527 in combination with letrozole and N = 345 in combination with fulvestrant) in randomized clinical studies in HR-positive, HER2-negative advanced BC or MBC [21]. This evidence concerns the gene ERBB2 and breast cancer.